Appeals Court Upholds Exec Exclusion; Rejects ‘Arbitrary’ Penalty Period

Washington Drug Letter
A U.S. appeals court has ruled HHS was “unambiguously” justified in excluding three former Purdue Pharma executives from federal healthcare programs after they pleaded guilty to charges the company illegally marketed and promoted its painkiller Oxycontin.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00